﻿{"id":30004,"date":"2025-11-11T14:26:57","date_gmt":"2025-11-11T07:26:57","guid":{"rendered":"https:\/\/nhathuocngocanh.com\/bp\/?p=30004"},"modified":"2025-11-11T14:34:19","modified_gmt":"2025-11-11T07:34:19","slug":"ribavirin","status":"publish","type":"post","link":"https:\/\/nhathuocngocanh.com\/bp\/ribavirin\/","title":{"rendered":"Ribavirin"},"content":{"rendered":"<p>Edition: BP 2025 (Ph. Eur. 11.6 update)<\/p>\n<p><strong>Action and use<\/strong><\/p>\n<p>Antiviral (hepatitis C, respiratory syncytial virus).<\/p>\n<p><strong>Preparation<\/strong><\/p>\n<p>Ribavirin Powder for Nebuliser Solution<\/p>\n<h2>DEFINITION<\/h2>\n<p>1-\u03b2-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide.<\/p>\n<p><strong>Content<\/strong><\/p>\n<p>98.0 per cent to 102.0 per cent (dried substance).<\/p>\n<h2>CHARACTERS<\/h2>\n<h3>Appearance<\/h3>\n<p>White or almost white, crystalline powder.<\/p>\n<h3>Solubility<\/h3>\n<p>Freely soluble in water, slightly soluble in ethanol (96 per cent), slightly soluble or very slightly soluble in methylene chloride.<\/p>\n<p>It shows polymorphism (5.9).<\/p>\n<h2>IDENTIFICATION<\/h2>\n<p>Infrared absorption spectrophotometry (2.2.24).<\/p>\n<p>Comparison\u00a0 ribavirin CRS.<\/p>\n<p>If the spectra obtained in the solid state show differences, dissolve the substance to be examined and the reference substance separately in methylene chloride R, evaporate to dryness and record new spectra using the residues.<\/p>\n<h2>TESTS<\/h2>\n<p><strong>pH (2.2.3)<\/strong><\/p>\n<p>4.0 to 6.5.<\/p>\n<p>Dissolve 0.200 g in carbon dioxide-free water R and dilute to 10.0 mL with the same solvent.<\/p>\n<p><strong>Specific optical rotation (2.2.7)<\/strong><\/p>\n<p>-33 to -37 (dried substance).<\/p>\n<p>Dissolve 0.250 g in water R and dilute to 25.0 mL with the same solvent. Determine the specific optical rotation within 10 min of preparing the solution.<\/p>\n<h3>Related substances<\/h3>\n<p>Liquid chromatography (2.2.29).<\/p>\n<p>Test solution Dissolve 50.0 mg of the substance to be examined in water for chromatography R and dilute to 100.0 mL with the same solvent.<\/p>\n<p>Reference solution (a) In order to produce impurity A in situ, mix 5.0 mL of the test solution and 5.0 mL of a 42 g\/L solution of sodium hydroxide R and allow to stand for 90 min. Neutralise with 5.0 mL of a 103 g\/L solution of hydrochloric acid R and mix well.<\/p>\n<p>Reference solution (b) Dilute 1.0 mL of the test solution to 100.0 mL with water for chromatography R. Dilute 1.0 mL of this solution to 10.0 mL with water for chromatography R.<\/p>\n<p>Reference solution (c) Dissolve 50.0 mg of ribavirin CRS in water for chromatography R and dilute to 100.0 mL with the same solvent.<\/p>\n<p>Column:<\/p>\n<p>\u2014 size: l = 0.15 m, \u00d8 = 4.6 mm;<\/p>\n<p>\u2014 stationary phase: spherical end-capped octadecylsilyl silica gel for chromatography R (3 \u00b5m) suitable for use with highly aqueous mobile phases;<\/p>\n<p>\u2014 temperature: 25 \u00b0C.<\/p>\n<p>Mobile phase:<\/p>\n<p>\u2014 mobile phase A: dissolve 1.0 g of anhydrous sodium sulfate R in 950 mL of water for chromatography R, add 2.0 mL of a 5 per cent V\/V solution of phosphoric acid R, adjust to pH 2.8 with a 5 per cent V\/V solution of phosphoric acid R and dilute to 1000 mL with water for chromatography R;<\/p>\n<p>\u2014 mobile phase B: acetonitrile R1, mobile phase A (5:95 V\/V);<\/p>\n<table style=\"border-collapse: collapse; width: 100%; height: 84px;\">\n<tbody>\n<tr style=\"height: 21px;\">\n<td style=\"width: 33.3333%; height: 21px; text-align: center;\"><strong>Time (min)<\/strong><\/td>\n<td style=\"width: 33.3333%; height: 21px; text-align: center;\"><strong>Mobile phase A (per cent V\/V)<\/strong><\/td>\n<td style=\"width: 33.3333%; height: 21px; text-align: center;\"><strong>Mobile phase B (per cent V\/V)<\/strong><\/td>\n<\/tr>\n<tr style=\"height: 21px;\">\n<td style=\"width: 33.3333%; height: 21px; text-align: center;\">0 &#8211; 15<\/td>\n<td style=\"width: 33.3333%; height: 21px; text-align: center;\">100<\/td>\n<td style=\"width: 33.3333%; height: 21px; text-align: center;\">0<\/td>\n<\/tr>\n<tr style=\"height: 21px;\">\n<td style=\"width: 33.3333%; height: 21px; text-align: center;\">15 &#8211; 25<\/td>\n<td style=\"width: 33.3333%; height: 21px; text-align: center;\">100 \u2192 0<\/td>\n<td style=\"width: 33.3333%; height: 21px; text-align: center;\">0 \u2192 100<\/td>\n<\/tr>\n<tr style=\"height: 21px;\">\n<td style=\"width: 33.3333%; height: 21px; text-align: center;\">25 &#8211; 35<\/td>\n<td style=\"width: 33.3333%; height: 21px; text-align: center;\">0<\/td>\n<td style=\"width: 33.3333%; height: 21px; text-align: center;\">100<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Flow rate\u00a0 1.0 mL\/min.<\/p>\n<p>Detection\u00a0 Spectrophotometer at 220 nm.<\/p>\n<p>Injection\u00a0 5 \u00b5L of the test solution and reference solutions (a) and (b).<\/p>\n<p>Relative retention\u00a0 With reference to ribavirin (retention time = about 6 min): impurity A = about 0.8.<\/p>\n<p>System suitability\u00a0 Reference solution (a):<\/p>\n<p>\u2014 resolution: minimum 4.0 between the peaks due to impurity A and ribavirin.<\/p>\n<p>Limits:<\/p>\n<p>\u2014 correction factor: for the calculation of content, multiply the peak area of impurity A by 2.3;<\/p>\n<p>\u2014 impurity A: not more than twice the area of the principal peak in the chromatogram obtained with reference solution (b) (0.2 per cent);<\/p>\n<p>\u2014 unspecified impurities: for each impurity, not more than the area of the principal peak in the chromatogram obtained with reference solution (b) (0.10 per cent);<\/p>\n<p>\u2014 total: not more than 3 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.3 per cent);<\/p>\n<p>\u2014 disregard limit: 0.5 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.05 per cent).<\/p>\n<p><strong>Loss on drying (2.2.32)<\/strong><\/p>\n<p>Maximum 0.5 per cent, determined on 1.000 g by drying in an oven at 105 \u00b0C for 5 h.<\/p>\n<p><strong>Sulfated ash (2.4.14)<\/strong><\/p>\n<p>Maximum 0.1 per cent, determined on 1.0 g.<\/p>\n<h2>ASSAY<\/h2>\n<p>Liquid chromatography (2.2.29) as described in the test for related substances with the following modification.<\/p>\n<p>Injection\u00a0 Test solution and reference solution (c).<\/p>\n<p>Calculate the percentage content of C<sub>8<\/sub>H<sub>12<\/sub>N<sub>4<\/sub>O<sub>5<\/sub> from the declared content of ribavirin CRS.<\/p>\n<h2>STORAGE<\/h2>\n<p>Protected from light.<\/p>\n<h2>IMPURITIES<\/h2>\n<p><em>Specified impurities\u00a0 A.<\/em><\/p>\n<p><em>Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other\/unspecified impurities and\/or by the general monograph Substances for pharmaceutical use (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. Control of impurities in substances for pharmaceutical use)\u00a0 B, C, D, F, G.<\/em><\/p>\n<p>A. 1-\u03b2-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxylic acid,<\/p>\n<p>B. 1-\u03b1-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide (anomer),<\/p>\n<p>C. 1H-1,2,4-triazole-3-carboxylic acid,<\/p>\n<p>D. 1H-1,2,4-triazole-3-carboxamide,<\/p>\n<p>F. 1-(5-O-acetyl-\u03b2-D-ribofuranosyl)-1H-1,2,4-triazole-3-carboxamide (5\u2032-O-acetylribavirin),<\/p>\n<p>G. 1-\u03b2-D-ribofuranosyl-1H-1,2,4-triazole-5-carboxamide (N-isomer).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Edition: BP 2025 (Ph. Eur. 11.6 update) Action and use Antiviral (hepatitis C, respiratory syncytial virus). Preparation Ribavirin Powder for Nebuliser Solution DEFINITION 1-\u03b2-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide. Content 98.0 per cent to 102.0 per cent (dried substance). CHARACTERS Appearance White or almost white, crystalline powder. Solubility Freely soluble in water, slightly soluble in ethanol (96 per cent), slightly&#8230;<\/p>\n","protected":false},"author":5,"featured_media":30005,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[174],"tags":[],"class_list":["post-30004","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicinal-substances"],"acf":[],"_links":{"self":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/30004","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/comments?post=30004"}],"version-history":[{"count":2,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/30004\/revisions"}],"predecessor-version":[{"id":30017,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/30004\/revisions\/30017"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media\/30005"}],"wp:attachment":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media?parent=30004"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/categories?post=30004"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/tags?post=30004"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}